FENC Fennec Pharmaceuticals Inc.
10.36USD+0.10%Mkt Cap: 363.30M $P/E: —1d ago
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cispl…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap363.30M USD
Enterprise Value321.70M USD
Revenue (TTM)59.22M USD
Gross Profit40.88M USD
Net Income (TTM)-9.74M USD
Revenue/Share1.85 USD
Last Price10.36 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)10.92
PEG1.47
EV/EBITDA-314.98
EV/Revenue5.43
P/S6.13
P/B8.55
EPS (TTM)-0.12
EPS (Forward)0.95
52W Range
5.65062% of range13.25
52W High13.25 USD
52W Low5.650 USD
Profitability
Gross Margin91.57%
Oper. Margin9.72%
EBITDA Margin-1.73%
Profit Margin-21.82%
ROE-27.46%
ROA-13.81%
Growth
Revenue Growth85.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.47M USD
CapEx (TTM)—
FCF Margin1.81%
FCF Yield0.29%
Net Debt-41.25M USD
Net Debt/EBITDA40.39
Balance Sheet
Debt/Equity0.00
Current Ratio5.85
Quick Ratio5.21
Book Value/Sh1.21 USD
Cash/Share1.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.67 USD
Upside (mean)+70.5%
Target Range16.00 USD – 20.00 USD
16.00+70.5% to mean20.00
# Analysts6
Ownership
Shares Out.35.07M
Float19.88M
Insiders14.13%
Institutions54.39%
Short Interest
Short Ratio2.1d
Short % Float1.80%
Short % Out.1.55%
Shares Short545.04K
Short (prev mo.)532.10K
Technical
SMA 5011.15 (-7.0%)
SMA 2008.944 (+15.8%)
Beta1.23
S&P 52W Chg16.45%
Avg Vol (30d)191.68K
Avg Vol (10d)130.32K
Technical Indicators
RSI (14)42.5
MACD-0.2363
MACD Signal-0.1753
MACD Hist.-0.0610
BB Upper11.84 USD
BB Middle10.81 USD
BB Lower9.782 USD
BB Width19.07%
ATR (14)0.5555 USD
Vol Ratio (20d)0.80x